

MADD Antibody

Catalog No: #24025

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com


Description

Product Name	MADD Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	DEAE purified
Applications	E WB ICC
Species Reactivity	Hu Ms Rt
Immunogen Type	Peptide
Immunogen Description	Raised against a peptide corresponding to amino acids near the carboxy terminus of human MADD.
Target Name	MADD
Other Names	DENN
Accession No.	AAD12154
Formulation	Supplied in PBS containing 0.02% sodium azide.
Storage	Can be stored at -20°C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.


Application Details

Predicted MW: 200 to 220 kd

Images



Western blot analysis of MADD in whole cell lysates from the indicated cell lines with MADD antibody at 1:250 dilution.



Immunocytochemistry of MADD in human spleen tissue with MADD antibody at 10 ug/mL.

Background

MAP kinase-activating death domain protein (MADD) was initially identified as the type 1 tumor necrosis factor receptor (TNFR1) associated protein through their death domains. Overexpression of MADD activates MAP kinases ERK and JNK and induces the phosphorylation of cytosolic phospholipase A2. MADD shares 98% identity with DENN (for differentially expressed in neoplastic vs. normal cells), which was recently identified as a substrate for c-jun N-terminal kinase 3 (JNK3). MADD has greater than 94% overall identity to a GDP/GTP exchange protein Rab3-GEP. MADD is 87% identical to KIAA0358, a brain protein of unknown function. Identification of MADD as a component of the TNFR1 signaling complex and the similarity between MADD and Rab3-GEP provides a connection between TNFR1 activation and downstream MAP kinase activity through a guanine-nucleotide exchange protein.

Note: This product is for in vitro research use only and is not intended for use in humans or animals.